263 related articles for article (PubMed ID: 31280965)
21. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
22. Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center.
Haydu LE; Stollman JT; Scolyer RA; Spillane AJ; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Bonenkamp JJ; Thompson JF
Ann Surg Oncol; 2016 Apr; 23(4):1071-81. PubMed ID: 25956574
[TBL] [Abstract][Full Text] [Related]
23. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Staged Excision With Permanent Section Margin Control for Cutaneous Head and Neck Melanoma.
Moyer JS; Rudy S; Boonstra PS; Kraft C; Chinn SB; Baker SR; Schwartz JL; Bichakjian CK; Fullen D; Durham AB; Lowe L; Johnson TM
JAMA Dermatol; 2017 Mar; 153(3):282-288. PubMed ID: 28002553
[TBL] [Abstract][Full Text] [Related]
25. Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma.
Sladden MJ; Nieweg OE; Howle J; Coventry BJ; Thompson JF
Med J Aust; 2018 Feb; 208(3):137-142. PubMed ID: 29438650
[TBL] [Abstract][Full Text] [Related]
26. Association of Mohs Micrographic Surgery vs Wide Local Excision With Overall Survival Outcomes for Patients With Melanoma of the Trunk and Extremities.
Demer AM; Hanson JL; Maher IA; Liszewski W
JAMA Dermatol; 2021 Jan; 157(1):84-89. PubMed ID: 33084853
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
28. Surgical management of melanoma-in-situ using a staged marginal and central excision technique.
Möller MG; Pappas-Politis E; Zager JS; Santiago LA; Yu D; Prakash A; Kinal A; Clark GS; Zhu W; Puleo CA; Glass LF; Messina JL; Sondak VK; Cruse CW
Ann Surg Oncol; 2009 Jun; 16(6):1526-36. PubMed ID: 19050971
[TBL] [Abstract][Full Text] [Related]
29. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision.
Lens MB; Dawes M; Goodacre T; Bishop JA
Arch Surg; 2002 Oct; 137(10):1101-5. PubMed ID: 12361412
[TBL] [Abstract][Full Text] [Related]
30. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
31. Optimal resection margin for head and neck cutaneous melanoma.
Han AY; Dhanjani S; Pettijohn K; Patel PB; John MAS
Laryngoscope; 2019 Jun; 129(6):1386-1394. PubMed ID: 30408184
[TBL] [Abstract][Full Text] [Related]
32. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes of Mohs micrographic surgery for invasive melanoma of the trunk and proximal portion of the extremities.
Burnett ME; Brodland DG; Zitelli JA
J Am Acad Dermatol; 2021 Mar; 84(3):661-668. PubMed ID: 32763327
[TBL] [Abstract][Full Text] [Related]
34. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas.
Pasquali S; Haydu LE; Scolyer RA; Winstanley JB; Spillane AJ; Quinn MJ; Saw RP; Shannon KF; Stretch JR; Thompson JF
Ann Surg; 2013 Jul; 258(1):152-7. PubMed ID: 23426339
[TBL] [Abstract][Full Text] [Related]
35. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial.
Karakousis CP; Balch CM; Urist MM; Ross MM; Smith TJ; Bartolucci AA
Ann Surg Oncol; 1996 Sep; 3(5):446-52. PubMed ID: 8876886
[TBL] [Abstract][Full Text] [Related]
36. Margins of excision for cutaneous melanoma of the eyelid skin: the Collaborative Eyelid Skin Melanoma Group Report.
Esmaeli B; Youssef A; Naderi A; Ahmadi MA; Meyer DR; McNab A;
Ophthalmic Plast Reconstr Surg; 2003 Mar; 19(2):96-101. PubMed ID: 12644753
[TBL] [Abstract][Full Text] [Related]
37. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm.
Veronesi U; Cascinelli N; Adamus J; Balch C; Bandiera D; Barchuk A; Bufalino R; Craig P; De Marsillac J; Durand JC
N Engl J Med; 1988 May; 318(18):1159-62. PubMed ID: 3079582
[TBL] [Abstract][Full Text] [Related]
38. Margin of resection in the management of primary melanoma.
Cascinelli N
Semin Surg Oncol; 1998 Jun; 14(4):272-5. PubMed ID: 9588719
[TBL] [Abstract][Full Text] [Related]
39. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick).
Khayat D; Rixe O; Martin G; Soubrane C; Banzet M; Bazex JA; Lauret P; Vérola O; Auclerc G; Harper P; Banzet P;
Cancer; 2003 Apr; 97(8):1941-6. PubMed ID: 12673721
[TBL] [Abstract][Full Text] [Related]
40. One-cm Versus 2-cm Excision Margins for Patients With Intermediate Thickness Melanoma: A Matched-Pair Analysis.
Koskivuo I; Giordano S; Veräjänkorva E; Vihinen P
Dermatol Surg; 2015 Oct; 41(10):1130-6. PubMed ID: 26356846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
